Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo

ClinicalTrials.gov ID: NCT02192554

Public ClinicalTrials.gov record NCT02192554. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 11:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial

Study identification

NCT ID: NCT02192554
Recruitment status: Completed
Study type: Observational
Phase: Not listed
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Enrollment: 450 participants

Conditions and interventions

Conditions

Interventions

Not listed

Eligibility (public fields only)

Age range: Not listed
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 31, 2014
Primary completion: Apr 30, 2017
Completion: Apr 30, 2017
Last update posted: Apr 29, 2018

2014 – 2017

United States locations

U.S. sites: 28
U.S. states: 11
U.S. cities: 24

Facility	City	State	ZIP	Site status
Not listed	Tuscaloosa	Alabama	35404	—
Not listed	Costa Mesa	California	92626	—
Not listed	Lakewood	California	90805	—
Not listed	Orange	California	92868	—
Not listed	Redlands	California	92373	—
Not listed	Bradenton	Florida	34205	—
Not listed	Hialeah	Florida	33012	—
Not listed	Hialeah	Florida	33018	—
Not listed	Miami	Florida	33122	—
Not listed	Miami	Florida	33126	—
Not listed	Miami	Florida	33137	—
Not listed	Miami	Florida	33175	—
Not listed	Miami Springs	Florida	33166	—
Not listed	North Miami	Florida	33161	—
Not listed	Orange City	Florida	32763	—
Not listed	Sarasota	Florida	34239	—
Not listed	Atlanta	Georgia	30331	—
Not listed	Suwanee	Georgia	30024	—
Not listed	Quincy	Massachusetts	02169	—
Not listed	St Louis	Missouri	63128	—
Not listed	Toms River	New Jersey	08755	—
Not listed	Brooklyn	New York	11214	—
Not listed	New Hyde Park	New York	11040	—
Not listed	Charlotte	North Carolina	28270	—
Not listed	Hickory	North Carolina	28601	—
Not listed	Raleigh	North Carolina	27609	—
Not listed	Dallas	Texas	75243	—
Not listed	Waukesha	Wisconsin	53188	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 56 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02192554, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 29, 2018 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02192554 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →